ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATYR ATYR PHARMA INC

Post-Mkt 10-28 16:38:20 EDT

0.1284

+0.0044

+3.55%

盘后0.1300

+0.0016+1.25%

16:37 EDT

High0.1301	Low0.1161	Vol3.37M
Open0.1200	D1 Closing0.1240	Amplitude11.29%
Mkt Cap12.58M	Tradable Cap12.32M	Total Shares97.99M
T/O421.05K	T/O Rate3.51%	Tradable Shares95.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":0.1284,"timestamp":1793217600000,"preClose":0.124,"halted":0,"volume":3370484,"hourTrading":{"tag":"盘后","latestPrice":0.13,"preClose":0.1284,"latestTime":"16:37 EDT","volume":6404,"amount":830.83568396,"timestamp":1793219851092,"change":0.0016,"changeRate":0.012461,"amplitude":0.063084},"delay":0,"changeRate":0.03548387096774183,"floatShares":95966000,"shares":97986634,"eps":-0.621383,"marketStatus":"Post-Mkt","change":0.0044,"latestTime":"10-28 16:38:20 EDT","open":0.12,"high":0.1301,"low":0.1161,"amount":421053.075914016,"amplitude":0.112903,"askPrice":0.1418,"askSize":100,"bidPrice":0.1122,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.621383,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1793232000000},"marketStatusCode":4,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":0.124,"preHourTrading":{"tag":"盘前","latestPrice":0.1187,"preClose":0.124,"latestTime":"09:29 EDT","volume":33990,"amount":4114.07672544,"timestamp":1793194199999,"change":-0.0053,"changeRate":-0.042742,"amplitude":0.049194},"postHourTrading":{"tag":"盘后","latestPrice":0.13,"preClose":0.1284,"latestTime":"16:37 EDT","volume":6404,"amount":830.83568396,"timestamp":1793219851092,"change":0.0016,"changeRate":0.012461,"amplitude":0.063084},"volumeRatio":1.092628,"impliedVol":1.3941,"impliedVolPercentile":0.4303},"requestUrl":"/m/hq/s/ATYR/wiki","defaultTab":"wiki","newsList":[{"id":"2678818108","title":"aTyr Pharma Announces 1-for-40 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2678818108","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678818108?lang=en_us&edition=fundamental","pubTime":"2026-10-27 21:07","pubTimestamp":1793106478,"startTime":"0","endTime":"0","summary":"aTyr Pharma Announces 1-for-40 Reverse Stock SplitaTyr Pharma will implement a 1-for-40 reverse stock split effective at 5 p.m. ET on October 28, 2026.Split-adjusted trading will begin October 29, 202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDL9npqDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ATYR","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BN0W2W23.USD","NDAQ","LU2210150020.SGD","SG9999014021.USD","BK4112","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","LU2095319765.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BCDF","BK4139","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014013.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678170124","title":"aTyr Pharma Announces One-for-40 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2678170124","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678170124?lang=en_us&edition=fundamental","pubTime":"2026-10-27 21:00","pubTimestamp":1793106006,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nTUA7ZNTZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676500469","title":"aTyr Pharma Announces Research Collaboration with Montefiore Einstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2676500469","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676500469?lang=en_us&edition=fundamental","pubTime":"2026-10-19 19:00","pubTimestamp":1792407601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nTUA8GVJ1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676511617","title":"aTyr Pharma Holds Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2676511617","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676511617?lang=en_us&edition=fundamental","pubTime":"2026-10-17 04:03","pubTimestamp":1792180991,"startTime":"0","endTime":"0","summary":"aTyr Pharma Holds Special Stockholder MeetingaTyr Pharma shareholders approved charter amendments authorizing a reverse stock split at the October 16, 2026, special meeting.The board retains discretio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nNDL3sWMQc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675514863","title":"aTyr Pharma Reports Journal of Biological Chemistry Paper Showing Anti-Fibrotic Effects of Atyr0101 in Lung Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2675514863","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675514863?lang=en_us&edition=fundamental","pubTime":"2026-10-13 20:09","pubTimestamp":1791893360,"startTime":"0","endTime":"0","summary":"aTyr Pharma reports Journal of Biological Chemistry paper showing anti-fibrotic effects of ATYR0101 in lung modelaTyr Pharma published Journal of Biological Chemistry data showing anti-fibrotic activi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDLlX9wR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4585","BCDF","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","SG9999014013.SGD","IE00BQXX3F31.USD","ATYR","BK4112","IE00BQXX3C00.GBP","LU2095319765.USD","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014005.SGD","SG9999014021.USD","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672176462","title":"aTyr Pharma Files Form 3 Initial Beneficial Ownership Statement for CFO Brandon Yaras","url":"https://stock-news.laohu8.com/highlight/detail?id=2672176462","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672176462?lang=en_us&edition=fundamental","pubTime":"2026-10-02 04:03","pubTimestamp":1790884988,"startTime":"0","endTime":"0","summary":"aTyr Pharma files Form 3 initial beneficial ownership statement for CFO Brandon YarasaTyr Pharma CFO Brandon Yaras filed an initial Form 3 disclosing employee stock options covering 237,592 shares.The","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL28MZy7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670649424","title":"Why is aTyr Pharma Stock (ATYR) Down 7% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2670649424","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670649424?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:49","pubTimestamp":1790264997,"startTime":"0","endTime":"0","summary":"Shares in biopharmaceutical firm aTyr Pharma ($ATYR) dropped 7% today despite hopes that a trial for its lung disease drug efzofitimod was back on ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-atyr-pharma-stock-atyr-down-7-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-atyr-pharma-stock-atyr-down-7-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669945074","title":"US Stocks on the MOVE-Charles River, Oracle, TD Synnex","url":"https://stock-news.laohu8.com/highlight/detail?id=2669945074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669945074?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:44","pubTimestamp":1790264673,"startTime":"0","endTime":"0","summary":"BUZZ-US STOCKS ON THE MOVE-Charles River, Oracle, TD SynnexSeptember 24 (Reuters)-Wall Street's main indexes dropped on Thursday as uncertainty over prospects for a resolution to the Middle East confl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL6N45G10O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OWL","AGNG","DBX","ACAD","CG","IXC","IEF","FSLR","MGM","DAVA","PMAX","LU","PWR","ATYR","NEM","CORD","P","DK","SFIX","OXY","KYTX","SNX","XOM","CRL","ROL","AU","CRWV","CTEC","IXJ","PIPR","VLO","SRZN","IHE","ORCL","XXII","ERX","GRML","TWST","WHLR","LLY","CVX","ARES","APA","VSNT","GETY","RSKD","TLT","VKTX","DRI","VOYG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669014467","title":"aTyr Rises as FDA Aligns on Late-Stage Lung Disease Study Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2669014467","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669014467?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:53","pubTimestamp":1790250805,"startTime":"0","endTime":"0","summary":"BUZZ-aTyr rises as FDA aligns on late-stage lung disease study plan** Shares of biotech firm aTyr PharmaATYR.Orise 5.6% to $0.40 premarket** Co says FDA agreed on the protocol for a planned late-stage study of efzofitimod in pulmonary sarcoidosis, an inflammatory lung disease that can scar the lungs** Global study will enroll about 372 patients comparing the experimental drug with placebo** Main goal is improved lung function; key secondary goal is better respiratory symptoms and quality of life** Company expects to begin study-related activities in Q4 2026 and pursue US and European regulatory submissions** Prior subgroup data showed clinically meaningful lung function benefits in pulmonary sarcoidosis patients with restrictive lung diseases** Co says future development of efzofitimod will require additional funding through equity, debt, partnerships or licensing deals** As of last close, stock down ~52% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL4N45G0YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669462909","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2669462909","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669462909?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:06","pubTimestamp":1790247978,"startTime":"0","endTime":"0","summary":"Digital Currency X Technology (DCX) shares were up 43% in recent Thursday premarket activity, reversing a nearly 30% loss in the previous session.aTyr Pharma (ATYR) stock was up 41% after the company ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4099","ATYR","SPHL","DCX","GRML","BK4139","BK4088"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461882","title":"aTyr Pharma Aligns with FDA on Phase 3 Efzofitimod Trial in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461882","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669461882?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:00","pubTimestamp":1790244050,"startTime":"0","endTime":"0","summary":"aTyr Pharma aligns with FDA on Phase 3 efzofitimod trial in pulmonary sarcoidosisaTyr Pharma aligned with the FDA on a Phase 3 efzofitimod trial in chronic, symptomatic pulmonary sarcoidosis with rest","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL6p5g2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","BK4588","LU2210150020.SGD","SG9999014005.SGD","ATYR","BCDF","BK4585","BK4112","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00BQXX3D17.EUR","BK4139","NDAQ","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669469061","title":"aTyr Pharma - to Initiate Study-Related Activities in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669469061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669469061?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:00","pubTimestamp":1790244001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA63BQDW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669469044","title":"aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2669469044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669469044?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:00","pubTimestamp":1790244001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA63BQDW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571406","title":"aTyr Pharma Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571406","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571406?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:07","pubTimestamp":1789157246,"startTime":"0","endTime":"0","summary":"aTyr Pharma announces special shareholder meetingaTyr Pharma will hold a special stockholder meeting in San Diego, California on Oct. 16, 2026.Shareholders will vote on authorizing the board to implement a reverse stock split at a ratio from 1-for-10 to 1-for-50.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL8Dd5QH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664691678","title":"aTyr Pharma Expects FDA Response by Mid-September on Efzofitimod Phase 3 Sarcoidosis Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2664691678","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664691678?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:36","pubTimestamp":1788294988,"startTime":"0","endTime":"0","summary":"aTyr Pharma expects FDA response by mid-September on efzofitimod Phase 3 sarcoidosis protocolaTyr Pharma expects an FDA response by mid-September on its June protocol submission for a planned Phase 3 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL8dv7gk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014021.USD","IE00BKPKM429.USD","BK4588","BK4139","LU2210149790.SGD","NDAQ","IE00BN0W2T93.GBP","BK4112","BCDF","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","BK4585","LU2210150020.SGD","SG9999014039.USD","ATYR","SG9999014005.SGD","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664286997","title":"aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2664286997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664286997?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:36","pubTimestamp":1788294969,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nTUA8PMY6F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077886","title":"aTyr Pharma Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077886","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077886?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:01","pubTimestamp":1788174076,"startTime":"0","endTime":"0","summary":"aTyr Pharma announces special shareholder meetingaTyr Pharma schedules a special shareholder meeting in San Diego on Oct. 16, 2026.Vote sought to authorize a reverse stock split, with the ratio set by","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLY73Zz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658193426","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Embecta Corporation (EMBC) and aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658193426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658193426?lang=en_us&edition=fundamental","pubTime":"2026-08-10 22:01","pubTimestamp":1786370462,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Embecta Corporation (EMBC) and aTyr Pharma (ATYR)....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-embecta-corporation-embc-and-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-embecta-corporation-embc-and-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0128526141.USD","BK4137","ATYR","BK4139","LU0029874061.USD","BK4585","HCSG","EMBC","LABU","XBI","BK4581","XLV","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626404","title":"ATyr Pharma to Cut 60% of Staff, Bring in New CFO in Restructuring Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626404","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626404?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:31","pubTimestamp":1786134660,"startTime":"0","endTime":"0","summary":"ATyr Pharma appointed a new finance chief and said it would lay off around 60% of its staff in an effort to conserve capital and prioritize the development of efzofitimod, its interstitial lung diseas","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ATyr Pharma to Cut 60% of Staff, Bring in New CFO in Restructuring Push","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657266426","title":"aTyr Pharma Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657266426","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657266426?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134041,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc reports results for the quarter ended June 30 - Earnings SummaryaTyr Pharma IncATYR.OQreported a quarterly adjusted loss of 11 cents per share for the quarter ended June 30, higher tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442HF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atyrpharma.com","stockEarnings":[{"period":"1week","weight":-0.2845},{"period":"1month","weight":-0.5934},{"period":"3month","weight":-0.7433},{"period":"6month","weight":-0.8464},{"period":"1year","weight":-0.8726},{"period":"ytd","weight":-0.8417}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0551},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1232},{"period":"ytd","weight":0.1287}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.727273,"avgChangeRate":0.035951},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.011862},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.068704},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.026181},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.082646},{"month":6,"riseRate":0.583333,"avgChangeRate":-0.008959},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.016959},{"month":8,"riseRate":0.25,"avgChangeRate":-0.046901},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.02279},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.022185},{"month":11,"riseRate":0.545455,"avgChangeRate":0.024303},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.061175}],"exchange":"NASDAQ","name":"ATYR PHARMA INC","nameEN":"ATYR PHARMA INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ATYR PHARMA INC,ATYR,ATYR PHARMA INC股票,ATYR PHARMA INC股票老虎,ATYR PHARMA INC股票老虎国际,ATYR PHARMA INC行情,ATYR PHARMA INC股票行情,ATYR PHARMA INC股价,ATYR PHARMA INC股市,ATYR PHARMA INC股票价格,ATYR PHARMA INC股票交易,ATYR PHARMA INC股票购买,ATYR PHARMA INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}